Scot Niglio
Overview
Explore the profile of Scot Niglio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Apolo A, Ballman K, Sonpavde G, Berg S, Kim W, Parikh R, et al.
N Engl J Med
. 2024 Sep;
392(1):45-55.
PMID: 39282902
Background: Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical...
2.
El Zarif T, Nassar A, Pond G, Zhuang T, Master V, Nazha B, et al.
J Natl Cancer Inst
. 2023 Aug;
115(12):1605-1615.
PMID: 37563779
Background: Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors....
3.
Apolo A, Msaouel P, Niglio S, Simon N, Chandran E, Maskens D, et al.
Am Soc Clin Oncol Educ Book
. 2022 May;
42:1-16.
PMID: 35609225
The role of adjuvant therapy in renal cell carcinoma and urothelial carcinoma is rapidly evolving. To date, the U.S. Food and Drug Administration has approved sunitinib and pembrolizumab in the...
4.
Lagana A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, et al.
JCO Precis Oncol
. 2019 Feb;
2018.
PMID: 30706044
Purpose: Multiple myeloma (MM) is a malignancy of plasma cells, with a median survival of 6 years. Despite recent therapeutic advancements, relapse remains mostly inevitable, and the disease is fatal...